Meeting
2017 ASCO Annual Meeting
Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer.
Authors
Oladapo O. Yeku
Memorial Sloan Kettering Cancer Center, New York, NY
Oladapo O. Yeku , Terence Purdon , David R. Spriggs , Renier J. Brentjens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Cellular Immunotherapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3050)
DOI
10.1200/JCO.2017.35.15_suppl.3050
Abstract #
3050
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer.
First Author: Oladapo O. Yeku
Poster
2023 ASCO Annual Meeting
Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.
First Author: Mason Webb
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment.
First Author: Pedro Cabrales